Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis.

ABSTRACT:

Background

Metaplastic breast carcinoma (MpBC) is a rare breast cancer subtype frequently exhibiting triple-negative receptor status and poor response to chemotherapy. The optimal treatment sequence for MpBC remains unclear. This study evaluated overall survival (OS) in MpBC patients treated with neoadjuvant chemotherapy (NACT) versus upfront surgery and adjuvant chemotherapy using the National Cancer Database (NCDB).

Methods

A retrospective cohort analysis was performed using the NCDB to identify patients with stage I-III MpBC diagnosed from 2010 to 2019 who received either NACT followed by surgery or upfront surgery and adjuvant chemotherapy. Patients with metastatic disease or missing survival data were excluded. Kaplan-Meier and Cox proportional hazards models were used

SUBMITTER: Chichura AM 

PROVIDER: S-EPMC12494608 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature